Direkt zum Inhalt
Merck
  • Serum lidocaine levels and cutaneous side effects after application of 23% lidocaine 7% tetracaine ointment to the face.

Serum lidocaine levels and cutaneous side effects after application of 23% lidocaine 7% tetracaine ointment to the face.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (2013-01-03)
Patrick E McCleskey, Seema M Patel, Katherine A Mansalis, Amanda L Elam, Tina R Kinsley
ZUSAMMENFASSUNG

Few published studies have analyzed serum lidocaine levels and individual patient characteristics affecting metabolism after application of compounded topical anesthetics. To measure serum lidocaine levels during and cutaneous side effects after standardized application of 23% lidocaine/7% tetracaine compounded anesthetic to the face of healthy volunteers. Fifty-two volunteers were enrolled, and compounded 23% lidocaine/7% tetracaine ointment was applied to their faces for 2 hours. Lidocaine levels were determined every 30 minutes during application and for 2 hours after removal. Follow-up telephone calls 3 days later assessed cutaneous side effects. Median peak lidocaine level was 1.15 μg/mL, and the highest peak lidocaine level in an individual was 3.4 μg/mL. Higher serum lidocaine levels were found in men (p < .01), nonwhite volunteers (p = .02), and those with larger facial surface area (p = .04). Age and body mass index did not affect lidocaine levels. Irritant contact dermatitis was common, resulting in hyperpigmentation in some patients. Facial surface area, male sex, and nonwhite ethnicity were associated with higher serum lidocaine levels after topical application of lidocaine. Compounded anesthetics containing lidocaine should be used with caution under the direct supervision of a physician.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Tetracain -hydrochlorid, ≥99%
Sigma-Aldrich
Tetracain, ≥98% (TLC)
Supelco
Tetracain -hydrochlorid, Pharmaceutical Secondary Standard; Certified Reference Material
Tetracain -hydrochlorid, European Pharmacopoeia (EP) Reference Standard
Tetracain für die Systemeignung, European Pharmacopoeia (EP) Reference Standard